title: Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
abstract: The popular recreational drug, 'ecstasy', mainly contains 3,4-methylenedioxymethamphetamine (MDMA) as the psychotropic agent. MDMA is suspected of causing neurotoxic lesions to the serotonergic system as demonstrated by animal studies, examinations of human cerebrospinal fluid, and the first positron emission tomography (PET) studies using the serotonin transporter ligand [11C]-McN5652. Damage of serotonergic afferents might mediate long-lasting alterations of cerebral glucose metabolism as a secondary effect. To study a relationship between ecstasy use and long-lasting alterations, PET using 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) was performed in 93 ecstasy users and 27 subjects without any known history of illicit-drug abuse. As an index of glucose metabolism, mean normalized FDG uptake was determined in both groups using a computerized brain atlas, and was compared for a selected number of brain regions. FDG uptake was normalized in each individual by dividing local FDG uptake by the maximum FDG uptake in the individual's brain. Within the group of ecstasy users we examined the relationship between FDG uptake and cumulative ecstasy dose, time since last ecstasy ingestion at the time of PET scanning, and age at first ecstasy use, respectively. Normalized FDG uptake was reduced within the striatum and amygdala of ecstasy users when compared to controls. No statistically significant correlation of the FDG uptake and the cumulative dose of ecstasy was detected. A positive correlation was found in the cingulate between FDG uptake and the time since last ecstasy ingestion. As compared to the control group, normalized FDG uptake in the cingulate was reduced in ecstasy users who took ecstasy during the last 6 months, while it was elevated in former ecstasy users who did not consume ecstasy for more than 1 year. FDG uptake was significantly more affected in ecstasy users who started to consume ecstasy before the age of 18 years. In conclusion, ecstasy abuse causes long-lasting effects on glucose metabolism in the human brain. These effects are more severe in the case of very early abuse. However, several questions still remain to be answered, i.e. the correlation of the neuronal alterations and the history of ecstasy use (cumulative dose, and time since the last dose) and its reversibility.
authors.affiliation: Department of Nuclear Medicine, University Hospital Eppendorf, Hamburg, Germany. buchert@uke.uni-hamburg.de
authors.forename: R
authors.initials: R
authors.lastname: Buchert
authors.forename: J
authors.initials: J
authors.lastname: Obrocki
authors.forename: R
authors.initials: R
authors.lastname: Thomasius
authors.forename: O
authors.initials: O
authors.lastname: Väterlein
authors.forename: K
authors.initials: K
authors.lastname: Petersen
authors.forename: L
authors.initials: L
authors.lastname: Jenicke
authors.forename: K H
authors.initials: KH
authors.lastname: Bohuslavizki
authors.forename: M
authors.initials: M
authors.lastname: Clausen
mesh_terms: D000293:Adolescent; D000328:Adult; D001692:Biological Transport; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D002250:Carbon Radioisotopes; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D007546:Isoquinolines / Q000493:pharmacokinetics; D007700:Kinetics; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011985:Receptors, Serotonin / Q000378:metabolism; D012044:Regression Analysis; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D019966:Substance-Related Disorders / Q000000981:diagnostic imaging / Q000378:metabolism*; D013997:Time Factors; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
chemical_list: D002250:Carbon Radioisotopes; D006213:Hallucinogens; D007546:Isoquinolines; D019275:Radiopharmaceuticals; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D019788:Fluorodeoxyglucose F18; C058079:McN 5652; D018817:N-Methyl-3,4-methylenedioxyamphetamine